

PRODUCT INFORMATION



ARA 290 (acetate)

Item No. 34943

Formal Name: (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-amino-2-oxoethyl)-26-(3-amino-3-oxopropyl)-20-(2-carboxyethyl)-17-(3-guanidinopropyl)-2,5-bis(hydroxymethyl)-11,23-diisobutyl-14-methyl-4,7,10,13,16,19,22,25,28-nonaaxo-29-((S)-5-oxopyrrolidine-2-carboxamido)-3,6,9,12,15,18,21,24,27-nonaazadotriacontanedioic acid, acetate

Synonyms: Cibinetide, PHBSP, Pyroglutamate HBSP, Pyroglutamate Helix B Surface Peptide

MF: C₅₁H₈₄N₁₆O₂₁ • XC₂H₄O₂


FW: 1,257.3

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ARA 290 (acetate) is supplied as a solid. A stock solution may be made by dissolving the ARA 290 (acetate) in the solvent of choice, which should be purged with an inert gas. ARA 290 (acetate) is soluble in the organic solvent DMSO at a concentration of approximately 5 mg/ml.

Description

ARA 290 is a derivative of erythropoietin (EPO).¹ *In vivo*, ARA 290 (0.8 and 8 nmol/kg, i.p.) reduces plasma creatine, urea, and aspartate aminotransferase (AST) levels, markers of renal dysfunction, in a rodent model of renal ischemia-reperfusion injury. It decreases wound area in a rat model of punch biopsy-induced dermal injury and a rat model of decubitus ulcer.² ARA 290 (30 µg/kg, i.p.) reduces the latency to find the platform in the Morris water maze in a rat model of cortical impact-induced traumatic brain injury (TBI).³ It also reduces tactile allodynia in a rat model of neuropathic pain induced by spinal nerve injury (SNI).⁴

References

1. Brines, M., Patel, N.S.A., Villa, P., *et al.* Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. *Proc. Natl. Acad. Sci. USA* **105**(31), 10925-10930 (2008).
2. Erbayraktar, Z., Erbayraktar, S., Yilmaz, O., *et al.* Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. *Mol. Med.* **15**(7-8), 235-241 (2009).
3. Robertson, C.S., Garcia, R., Gaddam, S.S.K., *et al.* Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptide. *J. Neurotrauma* **30**(9), 765-774 (2013).
4. Swartjes, M., Niesters, M., and Dahan, A. Assessment of allodynia relief by tissue-protective molecules in a rat model of nerve injury-induced neuropathic pain. *Methods Mol. Biol.* **982**, 187-195 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/25/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM